

**Amendments to the Specification:**

Please amend the paragraph on page 4, lines 4-9 of International Patent Publication WO 01/12674 as shown in the following paragraph:

A non-limiting example of the monoclonal antibody is that produced by the hybridoma cell line deposited at the American Type Culture Collection (ATCC<sup>®</sup>), 10801 University Boulevard, Manassas, VA 20110-2209 on August 3, 1999, and having ATCC Accession No. PTA-450. The monoclonal antibody produced by the deposited hybridoma cell line having ATCC Accession No. PTA-450 is termed both MoAb 69 and VAC69 herein.

Please amend the paragraph on page 5, lines 10-13 of International Patent Publication WO 01/12674 as shown in the following paragraph:

A further aspect of the present invention is the hybridoma cell line deposited at the American Type Culture Collection (ATCC<sup>®</sup>), 10801 University Boulevard, Manassas, VA 20110-2209 on August 3, 1999, and having ATCC Accession No. PTA-450.

Please amend the paragraph on page 11, lines 19-29 of International Patent Publication WO 01/12674 as shown in the following paragraph:

The antigen on ovarian cancer cells is a single glycosylated polypeptide with a molecular weight of about 76 kDa to about 213 kDa, as determined by SDS-PAGE under reducing conditions; and it is absent from human peripheral blood mononuclear cells, absent from human B cells, and absent from human B cell myelogenic leukemia cells. An antigen recognized by the antibody of the invention is also present on liver cancer cells; thus, the liver cancer cell surface antigen has at least one epitope in common with the myeloma and ovarian cancer surface glycoprotein. An example of a hybridoma cell line that produces a monoclonal antibody which recognizes these antigens has been deposited at the American Type Culture Collection (ATCC<sup>®</sup>), 10801 University Boulevard, Manassas, VA 20110-2209, on August 3, 1999, and accorded ATCC Accession No. PTA-450.

Please amend the paragraph on page 29, lines 7-13 of International Patent Publication WO 01/12674 as shown in the following paragraph:

**1. Sources of cells** Human myeloma cell lines (U266, OPM, RPMI1860, KR12 and NCI H929), and chronic myelogenic leukemic cell line (K562) were purchased from the

American Type Culture Collection (ATCC®). Fresh human ovarian cancer, breast cancer, and liver cancer specimens were used. Cell lines of prostate cancer, LnCap (ATCC®); neuroblastoma cell line, NCI H2106 (ATCC®); and a cervical cancer, Caski (ATCC®) were also evaluated, as well as an EBV-transformed B cell tumor, Namalwa (ATCC®).